Corbus Pharmaceuticals Holdings, Inc.
(NASDAQ : CRBP)

( )
CRBP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.10%159.870.0%$1295.48m
AMGNAmgen, Inc. 2.21%255.131.3%$694.68m
SNSSSunesis Pharmaceuticals, Inc. 1.90%8.030.7%$561.33m
NVAXNovavax, Inc. 0.37%202.0980.0%$556.50m
ILMNIllumina, Inc. 0.98%401.963.5%$517.94m
GILDGilead Sciences, Inc. 0.72%65.771.0%$463.29m
REGNRegeneron Pharmaceuticals, Inc. 2.80%494.642.7%$449.68m
VRTXVertex Pharmaceuticals, Inc. 1.83%221.101.9%$383.88m
ALXNAlexion Pharmaceuticals, Inc. 1.45%157.542.0%$298.86m
BNTXBioNTech SE 6.12%140.720.0%$266.37m
BIIBBiogen, Inc. 1.75%270.441.7%$264.45m
EXASEXACT Sciences Corp. 2.66%130.5218.4%$192.20m
NBIXNeurocrine Biosciences, Inc. -0.05%95.004.9%$177.73m
CRSPCRISPR Therapeutics AG 0.60%123.850.6%$174.50m
SGENSeagen Inc. 3.77%149.645.8%$153.69m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.